- Shah, Neil Pravin
- Ciceri, P
- Müller, S
- O'Mahony, A
- Fedorov, O
- Filippakopoulos, P
- Hunt, JP
- Lasater, EA
- Pallares, G
- Picaud, S
- Wells, C
- et al.
Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clinical responses to targeted therapies. The difficulty of discovering kinase inhibitors with an appropriate multitarget profile has, however
